Literature DB >> 3925066

Interleukin 2 upregulates expression of its receptor on a T cell clone.

T R Malek, J D Ashwell.   

Abstract

Stimulation of a class II-restricted, antigen-specific T cell clone with interleukin 2 (IL-2) resulted in substantial increases in both cell surface IL-2 receptor (IL-2-R) and cytoplasmic IL-2-R messenger RNA (mRNA), whereas no increase was observed for cell-surface expression of Thy-1 and L3T4 antigens, and only a modest increase in Thy-1 mRNA was observed. These experiments demonstrate that, after initial acquisition of the IL-2-R, IL-2 as well as antigen is able to directly upregulate both the level of IL-2-R mRNA and cell surface IL-2-R molecules.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925066      PMCID: PMC2187624          DOI: 10.1084/jem.161.6.1575

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Isolation of cDNA clones encoding T cell-specific membrane-associated proteins.

Authors:  S M Hedrick; D I Cohen; E A Nielsen; M M Davis
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

2.  A monoclonal antibody discriminating between subsets of T and B cells.

Authors:  J Bruce; F W Symington; T J McKearn; J Sprent
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

3.  Monoclonal antibodies against rat immunoglobulin kappa chains.

Authors:  L L Lanier; G A Gutman; D E Lewis; S T Griswold; N L Warner
Journal:  Hybridoma       Date:  1982

4.  Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes.

Authors:  G H Reem; N H Yeh
Journal:  Science       Date:  1984-07-27       Impact factor: 47.728

5.  Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex.

Authors:  T R Malek; R J Robb; E M Shevach
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

6.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

7.  Purification and partial sequence analysis of human T-cell growth factor.

Authors:  R J Robb; R M Kutny; V Chowdhry
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

Review 8.  Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity.

Authors:  D P Dialynas; D B Wilde; P Marrack; A Pierres; K A Wall; W Havran; G Otten; M R Loken; M Pierres; J Kappler
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

9.  Mouse immunoglobulin D: construction and characterization of a cloned delta chain cDNA.

Authors:  J F Mushinski; F R Blattner; J D Owens; F D Finkelman; S W Kessler; L Fitzmaurice; M Potter; P W Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Antigen presentation by resting B cells. Radiosensitivity of the antigen-presentation function and two distinct pathways of T cell activation.

Authors:  J D Ashwell; A L DeFranco; W E Paul; R H Schwartz
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

View more
  25 in total

1.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

2.  A soluble factor from Trypanosoma brucei rhodesiense that prevents progression of activated human T lymphocytes through the cell cycle.

Authors:  M B Sztein; F Kierszenbaum
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

3.  Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA.

Authors:  N Oyaizu; N Chirmule; V S Kalyanaraman; W W Hall; R Pahwa; M Shuster; S Pahwa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

4.  Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation.

Authors:  T A Poulton; A Gallagher; R C Potts; J S Beck
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

5.  Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice.

Authors:  Connor J Dwyer; Allison L Bayer; Carmen Fotino; Liping Yu; Cecilia Cabello-Kindelan; Natasha C Ward; Kevin H Toomer; Zhibin Chen; Thomas R Malek
Journal:  Sci Signal       Date:  2017-12-19       Impact factor: 8.192

Review 6.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Interleukin-2 effects on human B cells activated in vivo.

Authors:  T Miyawaki; T Suzuki; J L Butler; M D Cooper
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  IL-2R signaling is essential for functional maturation of regulatory T cells during thymic development.

Authors:  Guoyan Cheng; Aixin Yu; Michael J Dee; Thomas R Malek
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

10.  Interleukin 2 activity in peripheral blood mononuclear cells of patients with gynecologic malignancies.

Authors:  Y Kikuchi; T Kita; K Oomori; M Miyauchi; I Iwano; I Kizawa
Journal:  Med Oncol Tumor Pharmacother       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.